CoChat

Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?

Open access
Kariuki, Samuel, Kering, Kelvin, Wairimu, Celestine, Onsare, Robert, Mbae, Cecilia · 2022 · Infection and Drug Resistance

The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index; 74 of the 94 sources its claims cite were checked for support.

Abstract

Introduction: Although antimicrobials have traditionally been used to treat infections and improve health outcomes, resistance to commonly used antimicrobials has posed a major challenge. An estimated 700,000 deaths occur globally every year as a result of infections caused by antimicrobial-resistant pathogens. Antimicrobial resistance (AMR) also contributes directly to the decline in the global economy. In 2019, sub-Saharan Africa (SSA) had the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions. Methods: We searched PubMed for articles relevant to AMR in pathogens in the WHO-GLASS list and in other infections of local importance in SSA. In this review, we focused on AMR rates and surveillance of AMR for these priority pathogens and some of the most encountered pathogens of public health significance. In addition, we reviewed the implementation of national action plans to mitigate against AMR in countries in SSA. Results and Discussion: The SSA region is disproportionately affected by AMR, in part owing to the prevailing high levels of poverty, which result in a high burden of infectious diseases, poor regulation of antimicrobial use, and a lack of alternatives to ineffective antimicrobials. The global action plan as a strategy for prevention and combating AMR has been adopted by most countries, but fewer countries are able to fully implement country-specific action plans, and several challenges exist in many settings. Conclusion: A concerted One Health approach will be required to ramp up implementation of action plans in the region. In addition to AMR surveillance, effective implementation of infection prevention and control, water, sanitation, and hygiene, and antimicrobial stewardship programs will be key cost-effective strategies in helping to tackle AMR.

Overview

CoChat Summary

TL;DR

This review summarizes antimicrobial resistance rates among WHO-GLASS and locally important pathogens in sub-Saharan Africa and assesses national action plan implementation. It reports that SSA has the highest AMR-attributable mortality and that NAP implementation remains limited by funding, surveillance, and multisectoral coordination gaps.

Key findings

  • In 2019, SSA had the highest AMR-attributable mortality rate (23.5 deaths per 100,000), with Western SSA highest at 27.3 deaths per 100,000; globally, 4.95 million deaths were associated with AMR and 1.27 million were attributable to AMR.
  • Resistance was widespread among reviewed pathogens: diarrheagenic E. coli prevalence ranged from 14.7% to 82%; multidrug-resistant S. Typhi subclade 4.3.1 prevalence ranged from 60.4% to 97%; MRSA prevalence ranged from 1.25% to 53.4%; carbapenem-resistant P. aeruginosa prevalence ranged from 6% to 34.8%; and East Africa had the highest A. baumannii carbapenem resistance prevalence at 23%.
  • NAP implementation was limited: 11 (25%) of 44 SSA countries had NAPs on AMR; 32% performed routine AMR surveillance on clinical pathogens and 2% on veterinary pathogens; 59% had a dedicated National Reference Laboratory; by February 2022, 15 SSA countries had fully developed NAPs. Thematic performance was 38±12% for awareness creation and training, 18±13% for surveillance, 33±13% for infection prevention and control, 28±23% for optimal antimicrobial use, and 59±12% for multisector and One Health collaboration.
  • Burden estimates included 141,918 cholera infections per year in SSA; approximately 1.5 million typhoid cases and 19,900 deaths annually in SSA, accounting for about 17% of global typhoid deaths; 421,600 invasive non-typhoidal Salmonella cases and 66,520 deaths in SSA; and 31% of neonatal sepsis mortalities (690,000) plausibly attributed to antimicrobial-resistant infections.

Methods

  • Narrative review of English original articles and reviews retrieved from PubMed and Google Scholar, covering the WHO-Africa region divided into Western, Eastern, Central, and Southern SSA; search terms included antimicrobial resistance, multi-drug resistance, sub-Saharan Africa, surveillance, global action plan, national action plan, and One Health approach; articles published between 2000 and 2022 were considered.
  • Pathogens were selected as WHO-GLASS priority pathogens plus Vibrio cholerae; inclusion criteria covered articles on selected pathogens from SSA countries, articles reporting antibiotic resistance rates and genes, and both monomicrobial and polymicrobial studies; exclusions were non-WHO-GLASS pathogens, articles from beyond SSA, conference abstracts, intervention trials, and duplicates.
  • The review presents resistance rates from cited studies in tables and discusses NAP implementation; it does not report a pooled meta-analysis.

Limitations

  • The paper states that precise burden estimates for resistant K. pneumoniae in SSA are lacking and that available data are generated in referral/research/university hospitals, which do not represent the broad range of healthcare settings; it also states that few A. baumannii reports come from low-income countries, making prevalence estimates difficult.
  • The paper states that the paucity of data in SSA on AMR prevalence and antimicrobial use is a major impediment, and it lists NAP implementation challenges including inadequate funding, poor coordination, inadequate surveillance data, poor infrastructure and health systems, staffing shortages, and lack of monitoring and quality assurance systems.
  • Evident from the text: as a narrative review using PubMed/Google Scholar and heterogeneous published studies, resistance rates are not pooled or systematically appraised, and many estimates come from single-center or referral-hospital studies that may not be generalizable.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/idr.s342753

Cites

190 of 190 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Resistance elements inserted into the novel pVC_ESBL plasmid in Kenyan cholera strains.
Figure 1 Resistance elements inserted into the novel pVC_ESBL plasmid in Kenyan cholera strains.CC BY-NC · PubMed Central
Figure 2 There are three main regions on the pVC_ESBL: SXT R319 carrying the floR-dhfrA1-strA-StrB-sul2 genes, class 1 integron carrying aadB-arr2-blaTEM1B-cmlA-blaOXA-10-arr-2-aadA1 cassettes and with sul1 and a truncated qacEΔ1 gene at the 3’ conserved end, and resistance genes inserted into the plasmid backbone encoding resistance to blaCTX-M-15), aac(3)-IIc that confer resistance to streptomycin, kanamycin, and tobramycin, and a putative gene for tunicamycin resistance.
Figure 2 There are three main regions on the pVC_ESBL: SXT R319 carrying the floR-dhfrA1-strA-StrB-sul2 genes, class 1 integron carrying aadB-arr2-blaTEM1B-cmlA-blaOXA-10-arr-2-aadA1 cassettes and with sul1 and a truncated qacEΔ1 gene at the 3’ conserved end, and resistance genes inserted into the plasmid backbone encoding resistance to blaCTX-M-15), aac(3)-IIc that confer resistance to streptomycin, kanamycin, and tobramycin, and a putative gene for tunicamycin resistance.CC BY-NC · PubMed Central

Verification

Claims the paper makes

50 Valid · 5 Not valid · 14 Not checked · 32 Own results and interpretations

38 more claims · 18 with their cited sources checked

Create a free account to see all 101 claims and to verify the 4 references still open.

See all claims — free account
  • Probably not a substantial claim. 27
  • It may state two separate claims as one. 42

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 190 references

Research works printed but not linked: 6

  1. 2014, Estimating the Economic Costs of Antimicrobial Resistance
  2. Webale, 2020, Gastroenterol Hepatol Bed Bench, 13, 238
  3. Kanteh, 2021, Microb Genom, 7, 000677
  4. Cornick, 2021, Microb Genom, 7, 000703
  5. 2022, StatPearls
  6. Murray, 2022, Lancet, 399, 629, 10.1016/S0140-6736(21)02724-0 · DOI · Paper page

Cited by

See all 245

Metadata

Authors
Kariuki, S., Kering, K., Wairimu, C., Onsare, R., & Mbae, C.
Affiliations
Kenya Medical Research Institute (KE)
Corresponding author
  • Kariuki, Samuel
  • Kering, Kelvin
  • Wairimu, Celestine
  • Mbae, Cecilia
Venue
Infection and Drug Resistance
Published
2022-07
Volume
Volume 15
Pages
3589-3609
ISSN
1178-6973 (ISSN-L)
OpenAlex
W4284678172
Cited by
245
References
189
Citations by year
2026: 72 · 2025: 92 · 2024: 53 · 2023: 27 · 2022: 1
FWCI
5.80
Type
journal article
Language
en
Open access
Locations
  • Infection and Drug Resistance (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc-sa)
Funders
  • Wellcome Trust (215675/Z/19/Z)
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (R01AI099525)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Salmonella and Campylobacter epidemiology
Keywords
antimicrobial resistance, antimicrobial resistance surveillance, sub-Saharan Africa, national action plans, One Health, antimicrobial stewardship, infection control, water, sanitation and hygiene, antimicrobial use regulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? https://app.cochat.ai/papers/10.2147/idr.s342753
The paper
Kariuki, S., Kering, K., Wairimu, C., Onsare, R., & Mbae, C. (2022). Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? Infection and Drug Resistance. https://doi.org/10.2147/idr.s342753

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.